The 23andMe Special Committee released news today indicating their plan to take the company through the Chapter 11 process.   While I am disappointed that we have come to this conclusion and my bid was rejected, I am supportive of the company and I intend to be a bidder.   I have

📢 new preprint alert: So so excited to share our analysis on the impact of common and rare variants on single-cell gene expression in blood, using WGS and scRNA-seq data from nearly 2,000 individuals and 5.4m cells as part of TenK10K phase 1 🧬medrxiv.org/content/10.110… 🧵👇 (1/n)

our work on the molecular differences between transcription factor isoforms is out now in Molecular Cell! key point: 2/3rds of TF isos differ in important properties like DNA binding & transcriptional activity many are "negative regulators" that are misexpressed in cancer

When his son Max was diagnosed with a rare disease, our colleague Thomas turned to Gemini to better understand complex scientific papers — and even make new connections across the research community. His story is a powerful reminder of why we work on AI. ↓

The New York Times recently had an article on IVF and embryo selection which I think buries a few important ledes about these products ...

First, the company Genomic Prediction was reportedly providing consumers with an IQ predictor that they later realized does not work, and removed. This is a big deal. Most likely the predictor was just noise, as I've written about before: theinfinitesimal.substack.com/p/genomic-pred….

edgeR ftw

chatGPT o3 is amazing, I am in genuine awe

New online! Advances in single-cell DNA sequencing enable insights into human somatic mosaicism bit.ly/3EGIyxQ

Online now!✨RESEARCH: Sarah Hoelzl et al demonstrate that aging promotes reactivation of the inactive X chromosome in mice, and catalog escape genes using multi-omics Daniel Andergassen nature.com/articles/s4358… rdcu.be/ekm0I

1/ We're dedicating $100M to support American scientists facing funding cuts through the Lux Science Helpline, an expansion of our Lux Labs program. To compete in the future, innovation must be funded 🧪💡

YOUR KNICKS ARE EASTERN CONFERENCE FINALS BOUND

An atlas of transcription factor-driven gene programs across human cells Teichlab biorxiv.org/content/10.110…

Classic new yorkers

"... Failure to make this point clear risks sowing confusion and undermining trust in genetics research." Companies like this are profiting off the fruits of genetics research while making it more difficult to carry out. How entertaining. thessgac.org/_files/ugd/67a…

Can we build multimodal models by simply aligning pretrained unimodal models with limited paired data? We introduce STRUCTURE 🏗️: a lightweight, plug-and-play regularizer that preserves latent geometry to align frozen unimodal models using <1% of paired data typically used in

New perspective out now in Nature Genetics! nature.com/articles/s4158… We argue that current variant classifications oversimplify disease risk and propose an integrated Bayesian framework that unifies pathogenicity & penetrance.

A few thoughts on Herasight, the new embryo selection company. First, the post below and the white paper imply that competitors like Nucleus have been marketing and selling grossly erroneous risk estimates. This is shocking if true! 🧵

Completely insane decision to walk away from one of the most promising medical technologies, allowing the US to get smoked in this area of biotech by other countries with more foresight.

Longevity gene therapy paper retracted. First retraction for George Church. Situation involved BioViva, co. headed by unlikely longevity figure Liz Parrish. Best quote from co-author: “I have retired and I am in Greenland. I do not have to talk to you.” retractionwatch.com/2025/08/13/geo…